Literature DB >> 24740081

Workflow and maintenance characteristics of five automated laboratory instruments for the diagnosis of sexually transmitted infections.

Sam Ratnam1, Dan Jang2, Jodi Gilchrist2, Marek Smieja2, Andre Poirier3, Todd Hatchette4, Jean-Frederic Flandin5, Max Chernesky6.   

Abstract

The choice of a suitable automated system for a diagnostic laboratory depends on various factors. Comparative workflow studies provide quantifiable and objective metrics to determine hands-on time during specimen handling and processing, reagent preparation, return visits and maintenance, and test turnaround time and throughput. Using objective time study techniques, workflow characteristics for processing 96 and 192 tests were determined on m2000 RealTime (Abbott Molecular), Viper XTR (Becton Dickinson), cobas 4800 (Roche Molecular Diagnostics), Tigris (Hologic Gen-Probe), and Panther (Hologic Gen-Probe) platforms using second-generation assays for Chlamydia trachomatis and Neisseria gonorrhoeae. A combination of operational and maintenance steps requiring manual labor showed that Panther had the shortest overall hands-on times and Viper XTR the longest. Both Panther and Tigris showed greater efficiency whether 96 or 192 tests were processed. Viper XTR and Panther had the shortest times to results and m2000 RealTime the longest. Sample preparation and loading time was the shortest for Panther and longest for cobas 4800. Mandatory return visits were required only for m2000 RealTime and cobas 4800 when 96 tests were processed, and both required substantially more hands-on time than the other systems due to increased numbers of return visits when 192 tests were processed. These results show that there are substantial differences in the amount of labor required to operate each system. Assay performance, instrumentation, testing capacity, workflow, maintenance, and reagent costs should be considered in choosing a system.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24740081      PMCID: PMC4097743          DOI: 10.1128/JCM.03549-13

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  16 in total

1.  Standardized comparison of processing capacity and efficiency of five new-generation immunoassay analyzers.

Authors:  H A Hendriks; W Kortlandt; W M Verweij
Journal:  Clin Chem       Date:  2000-01       Impact factor: 8.327

2.  Performance of the Abbott RealTime CT/NG for detection of Chlamydia trachomatis and Neisseria gonorrhoeae.

Authors:  C A Gaydos; C P Cartwright; P Colaninno; J Welsch; J Holden; S Y Ho; E M Webb; C Anderson; R Bertuzis; L Zhang; T Miller; G Leckie; K Abravaya; J Robinson
Journal:  J Clin Microbiol       Date:  2010-07-28       Impact factor: 5.948

3.  Evaluation of three automated nucleic acid amplification systems for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in first-void urine specimens.

Authors:  P N Levett; K Brandt; K Olenius; C Brown; K Montgomery; G B Horsman
Journal:  J Clin Microbiol       Date:  2008-04-09       Impact factor: 5.948

4.  Time-Motion Analysis of Four Automated Systems for the Detection of Chlamydia trachomatis and Neisseria gonorrhoeae by Nucleic Acid Amplification Testing.

Authors:  James A Williams; Laura Eddleman; Amy Pantone; Regina Martinez; Stephen Young; Barbara Van Der Pol
Journal:  J Lab Autom       Date:  2013-11-06

5.  Comparison of the BD Viper System with XTR Technology to the Gen-Probe APTIMA COMBO 2 Assay using the TIGRIS DTS system for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae in urine specimens.

Authors:  Linda M Mushanski; Ken Brandt; Nicolette Coffin; Paul N Levett; Gregory B Horsman; Elliot L Rank
Journal:  Sex Transm Dis       Date:  2012-07       Impact factor: 2.830

Review 6.  Molecular methods and platforms for infectious diseases testing a review of FDA-approved and cleared assays.

Authors:  Rajyasree Emmadi; Jerry B Boonyaratanakornkit; Rangaraj Selvarangan; Venkatakrishna Shyamala; Barbara L Zimmer; Laurina Williams; Bonita Bryant; Ted Schutzbank; Michele M Schoonmaker; Jean A Amos Wilson; Leslie Hall; Preeti Pancholi; Kathryn Bernard
Journal:  J Mol Diagn       Date:  2011-08-25       Impact factor: 5.568

7.  Performance of the cobas CT/NG test compared to the Aptima AC2 and Viper CTQ/GCQ assays for detection of Chlamydia trachomatis and Neisseria gonorrhoeae.

Authors:  Barbara Van Der Pol; Oliver Liesenfeld; James A Williams; Stephanie N Taylor; Rebecca A Lillis; Barbara A Body; Mindy Nye; Carol Eisenhut; Edward W Hook
Journal:  J Clin Microbiol       Date:  2012-04-18       Impact factor: 5.948

8.  Comparison of three assays for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in SurePath Pap samples and the role of pre- and postcytology testing.

Authors:  M Chernesky; D Jang; E Portillo; M Smieja; J Kapala; C Doucette; J Sumner; R Ewert; C MacRitchie; J Gilchrist
Journal:  J Clin Microbiol       Date:  2012-01-18       Impact factor: 5.948

9.  Head-to-head comparison of second-generation nucleic acid amplification tests for detection of Chlamydia trachomatis and Neisseria gonorrhoeae on urine samples from female subjects and self-collected vaginal swabs.

Authors:  Max Chernesky; Dan Jang; Jodi Gilchrist; Todd Hatchette; André Poirier; Jean-Frederic Flandin; Marek Smieja; Sam Ratnam
Journal:  J Clin Microbiol       Date:  2014-04-02       Impact factor: 5.948

10.  Comparing the performance of six human papillomavirus tests in a screening population.

Authors:  J Cuzick; L Cadman; D Mesher; J Austin; L Ashdown-Barr; L Ho; G Terry; S Liddle; C Wright; D Lyons; A Szarewski
Journal:  Br J Cancer       Date:  2013-01-31       Impact factor: 7.640

View more
  9 in total

1.  Evaluation of the cobas Cdiff Test for Detection of Toxigenic Clostridium difficile in Stool Samples.

Authors:  Lance R Peterson; Stephen A Young; Thomas E Davis; Zi-Xuam Wang; John Duncan; Christopher Noutsios; Oliver Liesenfeld; John C Osiecki; Michael A Lewinski
Journal:  J Clin Microbiol       Date:  2017-09-27       Impact factor: 5.948

2.  Head-to-head comparison of second-generation nucleic acid amplification tests for detection of Chlamydia trachomatis and Neisseria gonorrhoeae on urine samples from female subjects and self-collected vaginal swabs.

Authors:  Max Chernesky; Dan Jang; Jodi Gilchrist; Todd Hatchette; André Poirier; Jean-Frederic Flandin; Marek Smieja; Sam Ratnam
Journal:  J Clin Microbiol       Date:  2014-04-02       Impact factor: 5.948

3.  Evaluation of Performance Characteristics of the Aptima HIV-1 Quant Dx Assay for Detection and Quantitation of Human Immunodeficiency Virus Type 1 in Plasma and Cervicovaginal Lavage Samples.

Authors:  Soya S Sam; Jaclynn R Kurpewski; Susan Cu-Uvin; Angela M Caliendo
Journal:  J Clin Microbiol       Date:  2016-02-03       Impact factor: 5.948

4.  Detection of antibiotic resistance is essential for gonorrhoea point-of-care testing: a mathematical modelling study.

Authors:  Stephanie M Fingerhuth; Nicola Low; Sebastian Bonhoeffer; Christian L Althaus
Journal:  BMC Med       Date:  2017-07-26       Impact factor: 8.775

5.  Comparison of the Aptima HIV-1 Quant Dx assay with the COBAS AmpliPrep/COBAS TaqMan HIV-1 v2.0 Test for HIV-1 viral load quantification in plasma samples from HIV-1-infected patients.

Authors:  Serena Longo; Isabella Bon; Giuseppina Musumeci; Alessia Bertoldi; Vanessa D'Urbano; Leonardo Calza; Maria Carla Re
Journal:  Health Sci Rep       Date:  2018-03-13

6.  Comparison of Three Nucleic Acid Amplification Tests and Culture for Detection of Group B Streptococcus from Enrichment Broth.

Authors:  Ji H Shin; David T Pride
Journal:  J Clin Microbiol       Date:  2019-05-24       Impact factor: 5.948

7.  HPV testing for cervical cancer screening: technical improvement of laboratory logistics and good clinical performance of the cobas 6800 in comparison to the 4800 system.

Authors:  Helena Frayle; Silvia Gori; Martina Rizzi; Bianca Nives Graziani; Elisa Vian; Paolo Giorgi Rossi; Annarosa Del Mistro
Journal:  BMC Womens Health       Date:  2019-03-25       Impact factor: 2.809

Review 8.  Sample-to-result molecular infectious disease assays: clinical implications, limitations and potential.

Authors:  Stacy G Beal; Naziheh Assarzadegan; Kenneth H Rand
Journal:  Expert Rev Mol Diagn       Date:  2016-01-11       Impact factor: 5.225

9.  Clinical Validation of the Onclarity Assay After Assay Migration to the High-Throughput COR Instrument Using SurePath Screening Samples From the Danish Cervical Cancer Screening Program.

Authors:  Ditte Møller Ejegod; Helle Pedersen; Birgitte Tønnes Pedersen; Christine Monceyron Jonassen; Agnes Kathrine Lie; Laila Solhaug Hulleberg; Marc Arbyn; Jesper Bonde
Journal:  Am J Clin Pathol       Date:  2022-03-03       Impact factor: 2.493

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.